New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Malignant transformation involves mutations that create tumor antigens, making cancers theoretically detectable by the host immune system.
• Cancers can express tissue-specific or developmental antigens, often with incomplete immune tolerance, and sometimes viral oncogenes.
• Despite antigenic presentation, progressive cancer growth indicates the host immune system is overcome.

Purpose of the Study:

• To explore the potential of cancer immunotherapeutics by enhancing T cell responses against tumors.
• To investigate how immune evasion mechanisms in cancer can be overcome.

Main Methods:

• Analysis of tumor mutations and antigen expression in relation to T cell recognition.
• Review of therapeutic cancer vaccination strategies.
• Examination of antibody-mediated immunotherapies, including checkpoint blockade and costimulatory activation.

Main Results:

• Tumor-specific mutations and antigen overexpression provide targets for T cell-mediated immunity.
• Therapeutic cancer vaccination can induce tumor-specific T cell responses.
• Intratumoral factors attenuate T cell function within the tumor microenvironment.

Conclusions:

• Combining therapeutic cancer vaccination with antibody-based modulation of T cell function (e.g., checkpoint blockade) can restore anti-tumor T cell activity.
• This integrated approach has the potential to convert sub-curative vaccines into effective cancer immunotherapeutics.